New 'Living Drug' trial targets tough stomach cancers
NCT ID NCT07333573
Summary
This early-stage study is testing a new type of CAR-T cell therapy, called XW-LTH-03, for people with advanced stomach cancer that has spread and no longer responds to standard treatments. The main goal is to see if the treatment is safe and what side effects it causes. Researchers will also look for early signs that it might help shrink tumors in these 42 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.